Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims of the application.

Listing of Claims

Claim 1. (Currently Amended) A pharmaceutical composition for nasal administration, comprising:

zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

Claim 2. (Currently Amended) The composition according to preferred embodiment Claim 1, wherein the composition is a solution of a 2:1 zolpidem/tartrate salt in a least one liquid medium selected from the group consisting of sterile purified water USP, sterile water for inhalation USP, saline, isotonic saline, and combinations thereof.

Claim 3. (Currently Amended) The composition according to preferred embodiment Claim 1, further comprising at least one pH buffer.

Claim 4. (Currently Amended) The composition according to preferred embodiment

Claim 1, further comprising at least one penetrating agent.

Claim 5. (Currently Amended) The composition according to preferred embodiment Claim 1, wherein the zolpidem is present in an amount ranging from 0.001 mg to about 250 mg.

Claim 6. (Currently Amended) A method for inducing sleep, comprising:

nasally administrating to a subject in need thereof a pharmaceutical composition comprising zolpidem, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.

Claim 7. (Currently Amended) The method according to preferred embodiment Claim 6, wherein the composition is a solution of a 2:1 zolpidem/tartrate salt in a least one liquid medium selected from the group consisting of sterile purified water USP, sterile water for inhalation USP, saline, isotonic saline, and combinations thereof.

Claim 8. (Currently Amended) The method according to preferred embodiment

Claim 6, wherein the composition further comprises at least one pH buffer.

Claim 9. (Currently Amended) The method according to preferred embodiment

Claim 6, further comprising at least one penetrating agent.

Claim 10. (Currently Amended) The method according to preferred embodiment Claim 6, wherein the active agent is present in an amount ranging from 0.001 mg to about 250 mg.

Claim 11. (New) The composition according to Claim 1, wherein the drug unit volume of active agent ranges from 0.001 ml to 4 ml.

Application No. Preliminary Amendment

Claim 12. (New) The composition according to Claim 1, wherein the weight/weight loading of active agent ranges from 0.01 % to 95 % by weight based on the total weight of the composition.

Claim 13. (New) The composition according to Claim 1, wherein the composition is in the form of a solution, an emulsion, a microemulsion, a nanoemulsion, a dispersion, a suspension, an elixir, drops, sprays, aerosols, syrups, gels or ointments.

Claim 14. (New) The composition according to Claim 1, wherein the composition is buffered to a pH of 3 to 10.